Do we need new therapies for noneosinophilic asthma?

P. O'Byrne (Hamilton, Canada)

Source: Annual Congress 2004 - Noneosinophilic asthma
Session: Noneosinophilic asthma
Session type: Major Symposium
Number: 2640
Disease area: Airway diseases

Slide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. O'Byrne (Hamilton, Canada). Do we need new therapies for noneosinophilic asthma?. Annual Congress 2004 - Noneosinophilic asthma

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Is there a need for pharmacoepidemiology in asthma and COPD?
Source: Annual Congress 2004 - Pharmacoepidemiology of obstructive lung disease: beyond clinical trials
Year: 2004

Recommendations of new therapies for severe asthma and the future
Source: Annual Congress 2013 –ERS/ATS Task Force report on severe asthma
Year: 2013


Recommended new therapies for severe asthma and the future
Source: International Congress 2014 – PG05 Severe asthma – highlights from the ERS/ATS workshop
Year: 2014




Airway inflammation in asthma: current and future targets and therapies
Source: Breathe 2010; 6: 245-252
Year: 2010

Targeting airway inflammation in asthma: current and future therapies
Source: Annual Congress 2009 - PG13 Asthma: pathology and treatment
Year: 2009



Targeting airway inflammation in asthma: current and future therapies
Source: Annual Congress 2009 - MP7 - Targeting airway inflammation in asthma: current and future therapies
Year: 2009


Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives
Source: Eur Respir Rev 2015; 24: 594-601
Year: 2015



Who should receive which biologic and why? Current and future approaches in severe asthma patients
Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what?
Year: 2021


Bronchial thermoplasty: a new therapeutic option for the treatment of severe, uncontrolled asthma in adults
Source: Eur Respir Rev 2014; 23: 510-518
Year: 2014



Biologic therapies in paediatric severe asthma
Source: ERS webinar 2020: Biologic therapies in paediatric severe asthma
Year: 2020


Translational research approaches for finding new therapeutic targets involved in viral-induced asthma and COPD exacerbation
Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD
Year: 2014


Use of alternative therapies in patients with asthma and COPD: is there any difference?
Source: Eur Respir J 2005; 26: Suppl. 49, 504s
Year: 2005

Rhinophototherapy: a new tool for the treatment of allergic rhinitis?
Source: ISSN=ISSN 1810-6838, ISBN=, page=174
Year: 2005

Budesonide/formoterol for maintenance and as needed — a new approach to asthma management in children
Source: Eur Respir J 2005; 26: Suppl. 49, 161s
Year: 2005

Pharmacological strategies for self-management of asthma exacerbations
Source: Eur Respir J 2006; 28: 182-199
Year: 2006



Are we really transforming asthma and COPD management with biologics?
Source: International Congress 2018 – State of the art session: Airways disease
Year: 2018


Measuring airway hyperresponsiveness: does it add to routine measures of clinical efficacy in guiding asthma therapy?
Source: Eur Respir J 2006; 28: Suppl. 50, 319s
Year: 2006

A pragmatic guide to choosing biologic therapies in severe asthma
Source: Breathe, 17 (4) 210144; 10.1183/20734735.0144-2021
Year: 2021